Product Overview of CureMetrix
CureMetrix is a pioneering healthcare technology company established in 2014, dedicated to enhancing the accuracy and efficiency of breast cancer detection through advanced artificial intelligence (AI) and deep learning technologies.
Purpose and Mission
CureMetrix aims to improve disease detection and survival rates globally, particularly in the realm of breast cancer. The company’s mission is to equip radiologists with objective, data-driven tools to support their evaluation of mammograms, leading to improved clinical outcomes, reduced healthcare costs, and increased patient assurance.
Key Products and Features
cmTriage™
- This is the first FDA-cleared triage software in the U.S. for mammography. It uses AI to help radiologists triage, sort, and prioritize their worklist based on suspicious cases that may need immediate attention. cmTriage analyzes digital two-dimensional (2D) mammograms captured by Full-Field Digital Mammography (FFDM) systems, identifies potential abnormalities, and flags them for radiologists to review.
cmAssist®
- This is a proprietary, investigational Computer-Aided Detection (CAD) system that leverages AI to assist radiologists in identifying, marking, and scoring regions of interest on screening mammograms. This tool is designed to support radiologists in making more accurate diagnoses by highlighting areas that may have been overlooked.
Functionality
- Image Analysis and Triage: CureMetrix’s software receives mammography images from PACS systems, de-identifies and encrypts them, and then transmits them to the cloud for AI-driven analysis. The system groups images by study, analyzes them, and produces results in the form of DICOM Structured Report (SR) files, which are then transmitted back to the radiologist’s system for review.
- Integration with Clinical Workflows: The platform is designed to operate seamlessly within existing clinical workflows, minimizing extra steps for radiologists and patients. It is easy to install and integrates with current imaging systems, ensuring that it does not disrupt the normal workflow of radiology departments.
- Reduction in Reading Time and False Positives: By automating the detection process, CureMetrix’s AI-powered solutions reduce the reading time for radiologists by 30% and decrease false positives by 63%. This significantly improves the efficiency and accuracy of mammogram interpretations.
- Enhanced Detection Capabilities: The AI technology has been trained on over 5 million images and can detect breast cancer up to five years earlier than human radiologists in some cases. This early detection capability has the potential to significantly increase cancer survival rates by identifying cancers at earlier, more treatable stages.
Benefits
- Improved Accuracy: By leveraging AI and deep learning, CureMetrix helps radiologists catch abnormalities that might have otherwise been missed, particularly in cases where cancers are obscured by dense tissue.
- Efficiency and Productivity: The automated triage and analysis reduce the workload on radiologists, allowing them to focus on more critical cases and make better, faster decisions.
- Patient Assurance: Patients can receive AI-assisted second opinions, which can alleviate anxiety and provide peace of mind, especially for those with a family history of breast cancer.
In summary, CureMetrix offers cutting-edge AI-driven solutions that enhance the accuracy, efficiency, and reliability of mammography screenings, ultimately contributing to better healthcare outcomes for women globally.